Abstract Library

#4116 A review of the Scottish national Peptide Receptor Radionuclide Therapy (PRRT) service with focus on patients with small bowel neuroendocrine tumors (SBNET) treated between April 2019 and March 2021

Introduction: Scottish National PRRT Service delivers 177Lu-Dotatate nationally at the Beatson West of Scotland Cancer Centre (BWoSCC). The NETTER-1 trial (Strosberg et al 2017) significantly changed the treatment and management of patients with gastroenteropancreatic NET (GEPNET). 177Lu-Dotatate demonstrated superiority in progression free survival (PFS) in patients with G1 and 2 midgut neuroendocrine tumors (NET). 177Lu-Dotatate 7.4 GBq 8 weekly gave 65% estimated progression free survival (PFS)at 20 months versus 10.8 % with 60mg octreotide intramuscularly 4 weekly (Strosberg et al 2017). Prior to this study everolimus was the most common 2nd line treatment for SBNET with a PFS of 14 months (Puscuddo et al 2017).

Conference:

Presenting Author:

Authors: Wotherspoon I, Charlick A, McIntosh D, Reed N,

Keywords: NETTER-1, Scottish PRRT Service,

#4094 Peptide Receptor Radionuclide Therapy improves progression free and overall survival in patients who progress after resection of gastroenteropancreatic NETs

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) improves progression-free-survival (PFS) in advanced midgut neuroendocrine tumors (NETs). Whether PRRT specifically improves survival in surgically managed gastroenteropancreatic (GEP) NET with progression is unknown.

Conference:

Presenting Author: Howe J

Authors: Borbon L, Sherman S, Breheny P, Ear P, Menda Y,

Keywords: gastroenteropancreatic, resection, progression, PRRT, neuroendocrine tumor,

#3962 Familial midgut neuroendocrine tumors (FM-NETs): Results of the nationwide TCF cohort from the GTE-RENATEN network

Introduction: The clinical specificities of familial midgut neuroendocrine tumors (FM-NET) have been poorly described.

Conference:

Presenting Author: de Mestier L

Authors: Hunaut T, Hercent A, Walter T, Buecher B, Lepage C,

Keywords: familial, midgut, neuroendocrine, tumors, carcinoid,

#3778 Biological behaviour and response to treatment of neuroendocrine ovarian metastases

Introduction: Neuroendocrine ovarian metastases (NOM) predominantly derive from midgut neuroendocrine tumors (NETs) and develop in about 25% of female patients. Little is known of the treatment response of NOM.

Conference:

Presenting Author:

Authors: Mulders M, de Lussanet de La Sablonière Q, van Velthuysen M, Hofland J, de Herder W,

Keywords: neuroendocrine, ovary, PRRT, SSA, oophorectomy, tumor, growth, rate, PFS, OS,

#3774 The role of the gut microbiome in patients with midgut neuroendocrine tumors

Introduction: When compared to other cancers, the prevalence of midgut neuroendocrine tumors (NETs) has disproportionally increased over the past decades. To date, very little progress has been made in the discovery of (epi)genetic drivers and treatment options of these tumors. Recent microbiome research has provided novel treatment targets among various cancer types. However, its role in midgut NETs and the Carcinoid Syndrome (CS), a frequently present syndrome of hormonal hypersecretion, has not been studied.

Conference:

Presenting Author:

Authors: Mulders M, Audhoe A, Kraaij R, van Koetsveld P, Feelders R,

Keywords: gut, microbiome, neuroendocrine, tumor, carcinoid, syndrome, diagnosis,